CBIO Catalyst Biosciences Inc.

5.66
+0.06  (+1%)
Previous Close 5.6
Open 5.39
52 Week Low 3.43
52 Week High 8.94
Market Cap $124,876,806
Shares 22,063,040
Float 21,904,361
Enterprise Value $7,755,024
Volume 329,967
Av. Daily Volume 238,488
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Marzeptacog alfa
Hemophilia
Phase 3
Phase 3
Phase 3 trial to commence late-2020.
Dalcinonacog alfa – DalcA
Hemophilia B
Phase 2b
Phase 2b
Phase 2b data presented at the virtual World Foundation of Hemophilia Virtual Summit, June 15, 2020 - 28 days of daily SQ dosing of DalcA achieved protective target FIX levels of >12% in all participants.

Latest News

  1. SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced that the United States Patent and Trademark Office (USPTO) has issued US Patent Number 10,781,435 B2 entitled "Modified Membrane Type Serine Protease 1 (MTSP-1) Polypeptides and Methods of Use." This patent covers Catalyst's portfolio of engineered proteases that selectively cleave and degrade complement factor 3 (C3), including the lead candidate CB 2782-PEG, a potential best-in-class treatment for dry AMD currently partnered with Biogen. These modified proteases inhibit complement activation and have the potential to treat multiple diseases in which dysregulated complement activation plays a role. The newly issued patent…

    SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced that the United States Patent and Trademark Office (USPTO) has issued US Patent Number 10,781,435 B2 entitled "Modified Membrane Type Serine Protease 1 (MTSP-1) Polypeptides and Methods of Use." This patent covers Catalyst's portfolio of engineered proteases that selectively cleave and degrade complement factor 3 (C3), including the lead candidate CB 2782-PEG, a potential best-in-class treatment for dry AMD currently partnered with Biogen. These modified proteases inhibit complement activation and have the potential to treat multiple diseases in which dysregulated complement activation plays a role. The newly issued patent provides protection until at least 2038.

    "CB 2782 demonstrates the power of our protease engineering platform and focus on the complement cascade. We plan to leverage our platform to expand the number of candidates we move into clinical development over the coming years," said Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences.

    About Catalyst Biosciences

    Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hematologic and complement-mediated disorders. Our protease engineering platform includes two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Our most advanced product candidate is marzeptacog alfa (activated) (MarzAA), a next-generation SQ FVIIa entering a Phase 3 registration study in late 2020. Our next late-stage product candidate is dalcinonacog alfa (DalcA), a next-generation SQ FIX, which has demonstrated efficacy and safety in a Phase 2b clinical trial in individuals with Hemophilia B. We have a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, that has demonstrated superiority compared with the Padua variant in preclinical models. Finally, we have a global license and collaboration agreement with Biogen for the development and commercialization of anti-complement Factor 3 (C3) pegylated CB 2782.

    Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about Catalyst's plans to move new product candidates into clinical development in the coming years, the potential benefits of products based on Catalyst's engineered protease platform, plans to enroll the first patient into a Phase 3 registration study of MarzAA in late 2020, the potential for MarzAA and DalcA to effectively and therapeutically treat hemophilia subcutaneously, the superiority of CB 2679d-GT over other gene therapy candidates and the Company's collaboration with Biogen for the development and commercialization of pegylated CB 2782 for the potential treatment of geographic atrophy-associated dry age-related macular degeneration. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed as a result of the COVID-19 virus and other factors, that trials may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of DalcA or MarzAA, including the generation of neutralizing antibodies, which has been observed in patients treated with DalcA, the risk that costs required to develop or manufacture the Company's products will be higher than anticipated, including as a result of delays in development and manufacturing resulting from COVID-19 and other factors, the risk that Biogen will terminate Catalyst's agreement, competition and other risks described in the "Risk Factors" section of the Company's quarterly report filed with the Securities and Exchange Commission on August 6, 2020, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

    Contact:

    Ana Kapor

    Catalyst Biosciences, Inc.

    Primary Logo

    View Full Article Hide Full Article
  2. SOUTH SAN FRANCISCO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced that Grant Blouse, Ph.D., senior vice president of translational research, will present at the Stifel Immunology and Inflammation Virtual Summit. Dr. Blouse will speak on a panel entitled: "The evolution of complement targeted therapies," taking place on Thursday, October 1, 2020, at 9:00 AM Eastern Time.

    To access a live webcast of the panel presentation, please click here.

    An archived webcast of the presentation will be available for 90 days on the Events and Presentations section on the Company's website.

    About Catalyst Biosciences
    Catalyst is a research and clinical development biopharmaceutical company focused…

    SOUTH SAN FRANCISCO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced that Grant Blouse, Ph.D., senior vice president of translational research, will present at the Stifel Immunology and Inflammation Virtual Summit. Dr. Blouse will speak on a panel entitled: "The evolution of complement targeted therapies," taking place on Thursday, October 1, 2020, at 9:00 AM Eastern Time.

    To access a live webcast of the panel presentation, please click here.

    An archived webcast of the presentation will be available for 90 days on the Events and Presentations section on the Company's website.

    About Catalyst Biosciences

    Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hematologic and complement-mediated disorders. Our protease engineering platform includes two late-stage clinical programs in hemophilia; a research program on the engineering of subcutaneous (SQ) complement inhibitors; and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Our most advanced product candidate is marzeptacog alfa (activated) (MarzAA), a next-generation SQ FVIIa entering a Phase 3 registration study in late 2020. Our next late-stage product candidate is dalcinonacog alfa (DalcA), a next-generation SQ FIX, which has demonstrated efficacy and safety in a Phase 2b clinical trial in individuals with Hemophilia B. We have a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, that has demonstrated superiority compared with the Padua variant in preclinical models. Finally, we have a global license and collaboration agreement with Biogen for the development and commercialization of anti-complement Factor 3 (C3) pegylated CB 2782.

    Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the potential benefits of products based on Catalyst's engineered protease platform, plans to enroll the first patients in a Phase 3 registration study of MarzAA in late 2020, the potential for MarzAA and DalcA to effectively and therapeutically treat hemophilia subcutaneously, the superiority of CB 2679d-GT over other gene therapy, and the development of anti-complement Factor 3 (C3) pegylated CB 2782 by Biogen. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed as a result of the COVID-19 pandemic and other factors, that trials may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of DalcA or MarzAA, including the generation of neutralizing antibodies, which has been observed in patients treated with DalcA, the risk that costs required to develop or manufacture the Company's products will be higher than anticipated, including as a result of delays in development and manufacturing resulting from COVID-19 and other factors, the risk that Biogen will terminate Catalyst's agreement, competition and other risks described in the "Risk Factors" section of the Company's quarterly report filed with the Securities and Exchange Commission on August 6, 2020, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

    Contact:

    Ana Kapor

    Catalyst Biosciences, Inc.

    Primary Logo

    View Full Article Hide Full Article
  3. SOUTH SAN FRANCISCO, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced that Nassim Usman, Ph.D., president and chief executive officer and Clinton Musil, chief financial officer of Catalyst Biosciences, will participate in fireside chats at two investor conferences in September: The Morgan Stanley Global Healthcare Conference and the Cantor Virtual Global Healthcare Conference. Details for each can be found below.

    Morgan Stanley Global Healthcare Conference 
    Date:Thursday, September 17, 2020
    Time:5:00 PM Eastern Time
    Webcast:MS webcast
    
     
    Cantor Virtual Global Healthcare Conference
    Date:Thursday, September 17, 2020
    Time:4:40 PM Eastern Time
    Webcast:Cantor webcast

    An archived webcast of the presentations…

    SOUTH SAN FRANCISCO, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced that Nassim Usman, Ph.D., president and chief executive officer and Clinton Musil, chief financial officer of Catalyst Biosciences, will participate in fireside chats at two investor conferences in September: The Morgan Stanley Global Healthcare Conference and the Cantor Virtual Global Healthcare Conference. Details for each can be found below.

    Morgan Stanley Global Healthcare Conference 

    Date:Thursday, September 17, 2020
    Time:5:00 PM Eastern Time
    Webcast:MS webcast
    

     
    Cantor Virtual Global Healthcare Conference

    Date:Thursday, September 17, 2020
    Time:4:40 PM Eastern Time
    Webcast:Cantor webcast

    An archived webcast of the presentations will be available for 90 days on the Events and Presentations page under the Investors section of the Company's website.

    About Catalyst Biosciences

    Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hematologic and complement-mediated disorders. Our protease engineering platform includes two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Our most advanced product candidate is marzeptacog alfa (activated) (MarzAA), a next-generation SQ FVIIa entering a Phase 3 registration study in late 2020. Our next late-stage product candidate is dalcinonacog alfa (DalcA), a next-generation SQ FIX, which has demonstrated efficacy and safety in a Phase 2b clinical trial in individuals with Hemophilia B. We have a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, that has demonstrated superiority compared with the Padua variant in preclinical models. Finally, we have a global license and collaboration agreement with Biogen for the development and commercialization of anti-complement Factor 3 (C3) pegylated CB 2782.

    Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the potential benefits of products based on Catalyst's engineered protease platform, plans to enroll the first patients in a Phase 3 registration study of MarzAA in late 2020, the potential for MarzAA and DalcA to effectively and therapeutically treat hemophilia subcutaneously, the superiority of CB 2679d-GT over other gene therapy, and the development of anti-complement Factor 3 (C3) pegylated CB 2782 by Biogen. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed as a result of the COVID-19 pandemic and other factors, that trials may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of DalcA or MarzAA, including the generation of neutralizing antibodies, which has been observed in patients treated with DalcA, the risk that costs required to develop or manufacture the Company's products will be higher than anticipated, including as a result of delays in development and manufacturing resulting from COVID-19 and other factors, the risk that Biogen will terminate Catalyst's agreement, competition and other risks described in the "Risk Factors" section of the Company's quarterly report filed with the Securities and Exchange Commission on August 6, 2020, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

    Contact:

    Ana Kapor

    Catalyst Biosciences, Inc.

    Primary Logo

    View Full Article Hide Full Article
  4. NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

    VANCOUVER, BC / ACCESSWIRE / August 18, 2020 / Softlab9 Technologies Inc. (CSE:SOFT)(OTC:SOFSF)(FRA:APO2) ("SOFT" or the "Company"), is pleased to announce that its target acquisition CleanGo GreenGo ("CleanGo") has signed a supply agreement with CBIO Brand Distribution International Inc., (NASDAQ:CBIO) to supply bulk concentrate material for CBIO's SaniGenix Naturals line of hard surface disinfectants and sanitizers.

    SaniGenix™ Naturals
    CBIO's CPG brand SaniGenix™ Naturals offers consumers an EPA approved line of disinfectants and sanitizers for hard surfaces.

    "We are so pleased to be able to offer consumers the choice to use a non-toxic green cleaner in their…

    NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

    VANCOUVER, BC / ACCESSWIRE / August 18, 2020 / Softlab9 Technologies Inc. (CSE:SOFT)(OTC:SOFSF)(FRA:APO2) ("SOFT" or the "Company"), is pleased to announce that its target acquisition CleanGo GreenGo ("CleanGo") has signed a supply agreement with CBIO Brand Distribution International Inc., (NASDAQ:CBIO) to supply bulk concentrate material for CBIO's SaniGenix Naturals line of hard surface disinfectants and sanitizers.

    SaniGenix™ Naturals
    CBIO's CPG brand SaniGenix™ Naturals offers consumers an EPA approved line of disinfectants and sanitizers for hard surfaces.

    "We are so pleased to be able to offer consumers the choice to use a non-toxic green cleaner in their defence against germs. Having CleanGo GreenGo™ as our strategic supplier for SaniGenix™ Naturals adds yet another unique and high performing CPG product to CBIO's suite of brands" says Lisa Little, President and CEO.

    Anthony Sarvucci, CEO of CleanGo said, "CleanGo is pleased to provide the power of emulsification to CBIO's line of products. We continue to validate our technology and the need for our product in today's sanitization market."

    About CleanGo GreenGo
    CleanGo GreenGo is an FDA and Health Canada approved Manufacturer of Green, Non-Toxic, and Biodegradable suite of cleaning products for industrial, commercial and consumer markets.

    CleanGo GreenGo, also manufactures hand sanitizer gel which is sold throughout the USA and Canada.

    CleanGo's products have been tested in 2015 in the USA to kill the human coronavirus. CleanGo's products are sold on various online platforms, including Amazon, as well as through distribution in retail, wholesale, and government agencies. CleanGo GreenGo utilizes a Patent Pending IP. The Patent was filed with the United States Patent and Trademark Office in February 2020 and currently holds a Patent Pending Status.

    About SoftLab9
    SoftLab9 Technologies Inc. is an international publicly traded company that specializes in the development of early staged companies. We provide access to capital, executive management and industry experience to grow our portfolio of companies.

    SoftLab9's experienced team bring new ideas and innovation based on science to find solution's to the current world we live in. Customers rely on quality, nontoxic products to keep their homes clean and their loved ones safe, now more than ever during these unprecedented international public health crisis.

    Cautionary Note:
    The Company is not making any express or implied claims that CleanGo GreenGo or any other product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time. Do not drink or consume any of the products at any time. Follow the instructions on the bottles. The products mentioned are meant to be used on surfaces and hands to sanitize to protect against bacteria and viruses. CleanGo GreenGo is not a cure, nor does it imply to be a cure for COVID-19.

    For further information please contact:
    Rahim Mohamed
    Chief Executive Officer
    Phone: (403) 605-9429

    https://www.soft-lab9.com/

    Paul Searle
    Corporate Communications
    Citygate Capital Corp
    Phone: (778) 240-7724

    NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

    Forward-Looking Information
    This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this presentation that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations, and orientations regarding the future, including without limitation statements related to the use of the proceeds of the Private Placement and the Company's prospect of success in executing its proposed plans, including its plans to complete the acquisition of CleanGo GreenGo. Forward-looking statements can often be identified by words such as "will", "plans", "expects", "may", "intends", "anticipates", "believes", proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions by management regarding the Company, including, without limitation, the Company's ability to acquire CleanGo GreenGo and obtain required regulatory approvals and the timing thereof. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required to execute its proposed business plans, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the Company's operations may also adversely affect the future results or performance of the Company. The Company can provide no guarantee that it will be successful in completing the Private Placement or completing the acquisition of CleanGo GreenGo. Investors are cautioned that forward looking statements are not guarantees of future performance or events and, accordingly are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. The forward-looking statements included in this news release are made as of the date hereof and the Company does not intend to update or revise any forward-looking statements, except as expressly required by law.

    SOURCE: Softlab9 Technologies Inc



    View source version on accesswire.com:
    https://www.accesswire.com/602298/Softlab9-Target-Acquisition-CleanGo-GreenGo-Signs-Supply-Agreement

    View Full Article Hide Full Article


  5. Vancouver, BC - TheNewswire - August 18th, 2020 - Softlab9 Technologies Inc. (CSE:SOFT, font-weight:normal)) (CSE:SOFT) (Frankfurt:APO2) (OTC:SOFSF) ("SOFT" or the "Company"), is pleased to announce that its target acquisition CleanGo GreenGo ("CleanGo") has signed a supply agreement with CBIO Brand Distribution International Inc., (NASDAQ:CBIO) to supply bulk concentrate material for CBIO's SaniGenix Naturals line of hard surface disinfectants and sanitizers.

    SaniGenix(TM) Naturals

    CBIO's CPG brand SaniGenix(TM) Naturals offers consumers an EPA approved line of disinfectants and sanitizers for hard surfaces.

    "We are so pleased to be able to offer consumers the choice to use a non-toxic green cleaner in their defence against germs.



    Vancouver, BC - TheNewswire - August 18th, 2020 - Softlab9 Technologies Inc. (CSE:SOFT, font-weight:normal)) (CSE:SOFT) (Frankfurt:APO2) (OTC:SOFSF) ("SOFT" or the "Company"), is pleased to announce that its target acquisition CleanGo GreenGo ("CleanGo") has signed a supply agreement with CBIO Brand Distribution International Inc., (NASDAQ:CBIO) to supply bulk concentrate material for CBIO's SaniGenix Naturals line of hard surface disinfectants and sanitizers.

    SaniGenix(TM) Naturals

    CBIO's CPG brand SaniGenix(TM) Naturals offers consumers an EPA approved line of disinfectants and sanitizers for hard surfaces.

    "We are so pleased to be able to offer consumers the choice to use a non-toxic green cleaner in their defence against germs. Having CleanGo GreenGo(TM) as our strategic supplier for SaniGenix(TM) Naturals adds yet another unique and high performing CPG product to CBIO's suite of brands" says Lisa Little, President and CEO.

    Anthony Sarvucci, CEO of CleanGo said, "CleanGo is pleased to provide the power of emulsification to CBIO's line of products. We continue to validate our technology and the need for our product in today's sanitization market."

    About CleanGo GreenGo

    CleanGo GreenGo is an FDA and Health Canada approved Manufacturer of Green, Non-Toxic, and Biodegradable suite of cleaning products for industrial, commercial and consumer markets.

    CleanGo GreenGo, also manufactures hand sanitizer gel which is sold throughout the USA and Canada.

    CleanGo's products have been tested in 2015 in the USA to kill the human coronavirus. CleanGo's products are sold on various online platforms, including Amazon, as well as through distribution in retail, wholesale, and government agencies. CleanGo GreenGo utilizes a Patent Pending IP. The Patent was filed with the United States Patent and Trademark Office in February 2020 and currently holds a Patent Pending Status.

    About SoftLab9

    SoftLab9 Technologies Inc. is an international publicly traded company that specializes in the development of early staged companies. We provide access to capital, executive management and industry experience to grow our portfolio of companies.

    SoftLab9's experienced team bring new ideas and innovation based on science to find solution's to the current world we live in. Customers rely on quality, nontoxic products to keep their homes clean and their loved ones safe, now more than ever during these unprecedented international public health crisis.

    Cautionary Note:

    The Company is not making any express or implied claims that CleanGo GreenGo or any other product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time. Do not drink or consume any of the products at any time. Follow the instructions on the bottles. The products mentioned are meant to be used on surfaces and hands to sanitize to protect against bacteria and viruses. CleanGo GreenGo is not a cure, nor does it imply to be a cure for COVID-19.

    For further information please contact:

    Rahim Mohamed

    Chief Executive Officer

    Phone: (403) 605-9429

    https://www.soft-lab9.com/

    Paul Searle

    Corporate Communications

    Citygate Capital Corp

    Phone: (778) 240-7724

    NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

    Forward-looking Information

    This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this presentation that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations, and orientations regarding the future, including without limitation statements related to the use of the proceeds of the Private Placement and the Company's prospect of success in executing its proposed plans, including its plans to complete the acquisition of CleanGo GreenGo. Forward-looking statements can often be identified by words such as "will", "plans", "expects", "may", "intends", "anticipates", "believes", proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions by management regarding the Company, including, without limitation, the Company's ability to acquire CleanGo GreenGo and obtain required regulatory approvals and the timing thereof. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required to execute its proposed business plans, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the Company's operations may also adversely affect the future results or performance of the Company. The Company can provide no guarantee that it will be successful in completing the Private Placement or completing the acquisition of CleanGo GreenGo. Investors are cautioned that forward looking statements are not guarantees of future performance or events and, accordingly are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. The forward-looking statements included in this news release are made as of the date hereof and the Company does not intend to update or revise any forward-looking statements, except as expressly required by law.

    NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

    Copyright (c) 2020 TheNewswire - All rights reserved.

    View Full Article Hide Full Article
View All Catalyst Biosciences Inc. News